Objective: To investigate the expression of aromatase protein, estrogen receptor (ER), progesterone receptor (PR) and nuclear antigen associated with cell proliferation Ki67 in endometrial diseases and their clinical significance in diagnosis and endocrine therapy of endometrial diseases.
Method: Expressions of aromatase, ER, PR and Ki-67 were detected with immunohistochemistry technic (streptavidin-peroxidase-biotin, SP) in 148 cases including 30 of endometrial hyperplasia, 30 of atypical proliferation and 88 of endometrial adenocarcinoma as observational group and 15 cases of proliferative endometrium and 15 cases of secretory endometrium as control group.
Results: Expression of aromatase protein and ER, PR, Ki67 in endometrial hyperplasia, atypical proliferation had no significant difference comparing with the proliferative endometrium group (P > 0.05). In endometrial adenocarcinoma, the expression of aromatase protein increased obviously (64%, 56/88), which was higher than in benign diseases [atypical proliferation group was 23% (7/30), endometrial hyperplasia group was 13% (4/30)] and control group significantly (P < 0.01). The positive expression of ER, PR in endometrial adenocarcinoma decreased [22% (19/88), 19% (17/88)], and Ki67 increased (41%, 36/88) and there was a significant difference compared with control group (P < 0.01). The positive rate of aromatase protein did not increase with the progress of clinical stage or grade of cellular differentiation. Aromatase was not consistent with ER, PR and Ki67 in endometrial adenocarcinoma.
Conclusion: Aromatase protein is related to the incidence of endometrial adenocarcinoma, and the expression of proteins (aromatase, ER, PR and Ki67) provides theoretical basis for understanding biological behavior of endometrial adenocarcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Adrenomedullin gene delivery rescues estrogen production in Leydig cells via the inhibition of TGF-β1/Smads signaling pathway.
Reprod Toxicol
January 2025
Department of Andrology, The First Affiliated Hospital, Hengyang Medical School, University of South China, China. Electronic address:
Article Synopsis
- The study investigates adrenomedullin's (ADM) role in protecting estrogen production in Leydig cells by targeting the TGF-β1/Smads signaling pathway.
- Treatment with ADM via recombinant adenovirus (Ad-ADM) in Leydig cells improved cell viability and hormone production in the presence of lipopolysaccharide (LPS), a compound that can induce cellular stress.
- Results indicated that Ad-ADM not only maintained testosterone production and aromatase activity but also reduced the harmful effects of TGF-β1 and Smads, suggesting that ADM supports the overall hormone balance in Leydig cells.
Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study.
Breast Cancer Res
January 2025
Department of Epidemiology (EM, JEB) and Nutrition (KJM), Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Kresge 505-B, Boston, MA, 02115, USA.
Background: Alcohol intake is associated with a higher risk of estrogen receptor-positive (ER+) breast cancer (BC), presumably through its confirmed ability to increase sex hormone levels. Whether consuming alcohol within the recommended limit of one serving per day increases sex hormone levels among postmenopausal women taking aromatase inhibitors (AI) to inhibit estrogen production remains unknown. Therefore, we compared sex hormone levels following white wine to levels following white grape juice among ER + BC survivors taking AIs.
View Article and Find Full Text PDFOxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
Cancer Res
January 2025
Medical College of Wisconsin, Milwaukee, WI, United States.
Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such persister cells may prevent recurrent disease.
View Article and Find Full Text PDFIn Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach.
Molecules
December 2024
Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche "STEBICEF", University of Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy.
Breast cancer remains one of the most prevalent and lethal malignancies in women, particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately 70% of cases. Traditional endocrine therapies, including aromatase inhibitors, selective estrogen receptor degraders/antagonists (SERDs), and selective estrogen receptor modulators (SERMs), have improved outcomes for metastatic ER+ breast cancer. However, resistance to these agents presents a significant challenge.
View Article and Find Full Text PDFEfficient sex hormone biosensors in Saccharomyces cerevisiae cells to evaluate human aromatase activity and inhibition.
Sci Rep
January 2025
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, China.
Yeast sex-hormone whole-cell biosensors are analytical tools characterized by long-time storage and low production cost. We engineered compact β-estradiol biosensors in S. cerevisiae cells by leveraging short (20-nt long) operators bound by the fusion protein LexA-ER-VP64-where ER is the human estrogen receptor and VP64 a strong viral activation domain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!